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Abstract 29 
Increasing evidence indicates that broadly neutralizing antibodies (bNAbs) play an important 30 
role in immune-mediated control of hepatitis C virus (HCV) infection, but the relative 31 
contribution of neutralizing antibodies targeting antigenic sites across the HCV envelope (E1 and 32 
E2) proteins is unclear. Here, we isolated thirteen E1E2-specific monoclonal antibodies (mAbs) 33 
from B cells of a single HCV-infected individual who cleared one genotype 1a infection and then 34 
became persistently infected with a second genotype 1a strain. These mAbs bound six distinct 35 
discontinuous antigenic sites on the E1 protein, the E2 protein, or the E1E2 heterodimer. Three 36 
antigenic sites, designated AS108, AS112 (an N-terminal E1 site), and AS146 were distinct from 37 
previously described Antigenic Regions (AR) 1-5 and E1 sites. Antibodies targeting four sites 38 
(AR3, AR4-5, AS108, and AS146) were broadly neutralizing. These mAbs also displayed 39 
distinct patterns of relative neutralizing potency (i.e., neutralization profiles) across a panel of 40 
diverse HCV strains, which led to complementary neutralizing breadth when they were tested in 41 
combination. Overall, this study demonstrates that HCV bNAb epitopes are not restricted to 42 
previously described antigenic sites, expanding the number of sites that could be targeted for 43 
vaccine development. 44 
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Importance 45 
Worldwide, more than 70 million people are infected with hepatitis C virus (HCV), which is a 46 
leading cause of hepatocellular carcinoma and liver transplantation. Despite the development of 47 
potent direct acting antivirals (DAAs) for HCV treatment, a vaccine is urgently needed due to the 48 
high cost of treatment and the possibility of reinfection after cure. Induction of multiple broadly 49 
neutralizing antibodies (bNAbs) that target distinct epitopes on the HCV envelope proteins is one 50 
approach to vaccine development. However, antigenic sites targeted by bNAbs in individuals 51 
with spontaneous control of HCV have not been fully defined. In this study, we characterize 52 
thirteen monoclonal antibodies (mAbs) from a single person who cleared an HCV infection 53 
without treatment, and we identify three new sites targeted by neutralizing antibodies. The sites 54 
targeted by these mAbs could inform HCV vaccine development. 55 
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Introduction 56 
Worldwide, more than 70 million people are infected with hepatitis C virus (HCV), which can 57 
lead to hepatocellular carcinoma and end-stage liver disease (1). Despite the development of 58 
potent direct acting antivirals (DAAs) for HCV treatment, the majority of persons with HCV are 59 
unaware of their infection, so they do not seek treatment and may continue to infect others (2). 60 
The high cost of treatment also limits access for many infected individuals, and those who are 61 
treated remain at risk for reinfection after cure (3-6). Few countries are on pace to achieve the 62 
goal of the World Health Organization (WHO) to eliminate HCV as a public health problem by 63 
2030, since nearly 60% of surveyed countries had more infections than cures in 2016 (7, 8). An 64 
effective preventative vaccine would play a major role in controlling the HCV pandemic. 65 
 66 
There is evidence from natural HCV infection that a vaccine could be effective. Approximately 67 
25% of acutely HCV-infected individuals clear their infections without treatment (9-11), and 68 
those who clear one infection clear subsequent infections more than 80% of the time, 69 
demonstrating that a protective anti-HCV immune response can develop naturally (12). We and 70 
others have shown that spontaneous clearance of HCV infection is associated with early 71 
development of broadly neutralizing antibodies (bNAbs) (10, 13), and we also demonstrated a 72 
mechanism by which bNAbs mediated spontaneous clearance of infection by two human 73 
subjects (14), suggesting that identification or design of antigens capable of inducing bNAbs is a 74 
reasonable approach to vaccine development. Therefore, clear definition of the epitopes targeted 75 
by bNAbs from individuals with clearance of infection is critical to inform vaccine design.  76 
 77 
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The majority of HCV envelope protein-specific human monoclonal antibodies (mAbs) were 78 
isolated from individuals with persistent HCV infection (15-25). Based upon E1E2 competition-79 
binding experiments and alanine scanning mutagenesis-E1E2-binding experiments with these 80 
mAbs, commonly targeted antigenic sites on the E1 and E2 proteins were designated Domains 81 
A-E or Antigenic Regions (AR) 1-5 (reviewed in (26-28)). Previously described mAbs targeting 82 
AR1/Domain C bind residues in the central beta sandwich (aa 486-566) and back layer (aa 597-83 
645) of E2 and are weakly- or non-neutralizing. MAbs targeting AR2 have narrow neutralizing 84 
breadth and also bind at the back layer of E2. MAbs targeting AR3/Domain B are often broadly 85 
neutralizing, targeting epitopes spanning the E2 front layer (aa 424-459) and CD81 binding loop 86 
(aa 519-535) (26, 29). Prototypical AR4 and AR5 mAbs, designated AR4A and AR5A, are also 87 
broadly neutralizing. These mAbs bind to epitopes that are still poorly defined, but both mAbs 88 
appear to bind near the C-terminus of E2, and each requires E1 and E2 in complex for binding 89 
(29). To date, few E1-specific mAbs have been isolated from infected humans. One example, 90 
designated IGH526, bound near the C-terminus of E1 and demonstrated relatively narrow 91 
neutralizing breadth (30).   92 
 93 
Recently, we and others isolated bNAbs from the B cells of individuals who cleared their HCV 94 
infections without treatment (31, 32). However, mAb isolation has been attempted from very few 95 
individuals who cleared HCV infection. Therefore, it remains unclear whether particular 96 
antigenic sites are consistently targeted by bNAbs in these individuals, and whether all 97 
commonly-targeted antigenic sites have been identified. 98 
 99 
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In this study, we isolated thirteen HCV envelope protein-specific mAbs from B cells of a single 100 
HCV-infected individual who cleared one genotype 1a infection and then became persistently 101 
infected with a second genotype 1a strain. These mAbs bound six distinct antigenic sites on the 102 
E2 protein, the E1E2 heterodimer, or at a discontinuous epitope near the N-terminus of E1. Three 103 
of these sites, including the N-terminal E1 site, were distinct from previously described AR1-5 104 
and E1 antigenic sites. Notably, mAbs targeting four of these antigenic sites were broadly 105 
neutralizing. These mAbs also displayed distinct patterns of relative neutralizing potency (i.e., 106 
neutralization profiles) across a panel of diverse HCV strains, which led to complementary 107 
neutralizing breadth when they were tested in combination.108 
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Materials and Methods 109 
Study Subjects. PBMCs were obtained from the BBAASH cohort (33). The study was approved 110 
by the Institutional Review Board of Johns Hopkins Hospital, and informed consent was 111 
obtained from all study participants. 112 
 113 
Cell Lines. HEK293T cells and Hep3B cells were obtained from American Type Culture 114 
Collection (ATCC). 115 
 116 
HCV Viral Load and Serology Testing. HCV viral loads (IU/mL) were quantified after RNA 117 
extraction with the use of commercial real-time reagents (Abbot HCV Real-time Assay) 118 
migrated onto a research-based real-time PCR platform (Roche 480 LightCycler). HCV 119 
seropositivity was determined using the Ortho HCV version 3.0 ELISA Test System (Ortho 120 
Clinical Diagnostics). 121 
 122 
C18 mAb Isolation. Human hybridomas were generated as described previously (31). In brief, 123 
cryopreserved PBMC samples from subject C18 were transformed with EBV, CpG, and 124 
additional supplements. After 7 days, cells from each well of the 384-well culture plates were 125 
expanded into four 96-well culture plates using cell culture medium containing irradiated 126 
heterologous human PBMCs and incubated for an additional 4 days. B cell culture supernatants 127 
were screened in ELISAs with E1E2-transfected cell lysates and in neutralization assays with 128 
HCVpp using autologous (strain 1a115) or heterologous (strain 1b38) HCV E1E2. Cells from 129 
wells with supernatants reacting with HCV antigens were fused with HMMA2.5 myeloma cells 130 
using an electrofusion technique. After fusion, hybridoma cell lines were cloned by limited 131 
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dilutions and single-cell fluorescence-activated cell sorting and expanded in post-fusion medium 132 
as previously described. HiTrap Protein G or HiTrap MabSelectSure columns were used to 133 
purify HCV-specific antibodies from filtered cell culture supernatants. 134 
 135 
Alanine Scanning and identification of probable binding residues. Alanine scanning 136 
mutagenesis was performed using a comprehensive HCV E1E2 mutation library (genotype 1a, 137 
strain H77) in which every residue of the E1E2 proteins was individually mutated to alanine. 138 
E1E2 alanine residues were mutated to serine (34). Cells expressing HCV E1E2 mutants were 139 
fixed, permeabilized, and immunostained with the indicated antibodies in duplicate. Mean 140 
cellular fluorescence was detected using an Intellicyt flow cytometer. To identify probable 141 
binding residues for each mAb, E1E2 residues were ranked from greatest to least effect of 142 
alanine mutation on mAb binding. Global misfolding positions, defined as residues at which 143 
alanine mutation reduced binding of all E1 and E1E2-specific mAbs, or all E2 and E1E2-specific 144 
mAbs to <75% of binding to wild type (121 of 555 E1E2 residues), were excluded as potential 145 
binding residues. For each mAb, after exclusion of global misfolding positions, up to 15 146 
mutations with greatest effect on binding that also reduced binding by at least 50% relative to 147 
wild type protein binding were selected as probable binding residues. The maximum number of 148 
probable binding residues was chosen based crystal structures of antibody/antigen complexes 149 
demonstrating that the average epitope includes 15+/-4 contact residues (35).  150 
 151 
Hierarchical clustering of mAbs based on relative binding across the E1E2 alanine 152 
scanning library. Hierarchical clustering analysis of alanine scanning-E1E2-binding values for 153 
each mAb was performed using code in R developed by Pierce et al. (26). Prior to analysis, 0% 154 
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binding values were converted to 1%, and all values were log10 transformed. Global misfolding 155 
positions were excluded. Ward’s minimum variance method in the hclust R package was used 156 
and an unrooted clustering tree was created with the ape R library. Bootstrap values for each 157 
cluster were generated from 10,000 replicates using the approximately unbiased method in the 158 
pvclust R package (36).  159 
 160 
E1E2 ELISA. ELISAs were performed as previously described (31). 293T cells were transfected 161 
with strain 1a31 or 1a53 E1E2 expression plasmids, and then lysed and used to coat ELISA 162 
plates. The E1E2 strain was chosen for each competition binding experiment to ensure adequate 163 
binding of all biotinylated mAbs. HEPC122 and HEPC153 were tested using strain 1a53, and all 164 
other mAbs were tested using strain 1a31. Blocking mAbs were added at 20 µg/mL, and 165 
biotinylated testing mAbs were added at either 0.4 µg/mL (HEPC122 and HEPC153) or at 2 166 
µg/mL (all other C18 mAbs). For denatured protein ELISA, E1E2 was boiled for 5 min in Tris-167 
buffered saline (TBS)-10% FCS containing 1.0% sodium dodecyl sulfate and 50 mM 168 
dithiothreitol prior to addition to GNA-lectin-coated ELISA plates.  169 
 170 
HCVpp Production and Neutralization. HCVpp were produced by lipofectamine-mediated 171 
transfection of HCV E1E2, pNL4-3.Luc.R-E, and pAdVantage (Promega) plasmids into 172 
HEK293T cells as previously described (11, 37, 38). Only HCVpp with an average RLU value 173 
>10X mock HCVpp values were used. Neutralization assays were performed as described 174 
previously with mAbs at a 50 µg/mL concentration with the exception of HEPC141 (40 µg/mL), 175 
or with serial 5-fold dilutions of mAbs starting at 100 µg/mL concentration (39). Fifty percent 176 
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inhibitory concentrations (IC50) were calculated from neutralization curves using nonlinear 177 
regression in Prism v7 (Graphpad Software). 178 
 179 
HCVcc neutralization assays. Chimeric genotype 2-6 HCVcc constructs (40, 41) were a gift of 180 
Jens Bukh, (Copenhagen University Hospital, Copenhagen, Denmark). HCVcc neutralization 181 
assays were performed as described elsewhere (42). Briefly, human hepatoma Huh7.5.1 cells (a 182 
gift of Charles Rice, The Rockefeller University, New York City, New York, USA) were 183 
maintained in DMEM supplemented with 10% fetal bovine serum and non-essential amino acids. 184 
8,000 Huh7.5.1 cells per well were plated in flat bottom 96 well tissue culture plates and 185 
incubated overnight at 37°C. The following day, HCVcc were mixed with mAb (50 μg/mL) then 186 
incubated at 37°C for 1 hour. Medium was removed from the cells and replaced with 50 µL of 187 
HCVcc/antibody mixture. The plates were placed in a CO2 incubator at 37°C overnight, after 188 
which the HCVcc were removed and replaced with 100 µL of Huh7.5.1 medium and incubated 189 
for 48 hours at 37°C. After 48 hours, medium was removed and cells were fixed and stained with 190 
primary anti-NS5A antibody 9E10 (a gift from Charles Rice, The Rockefeller University, New 191 
York City, New York, USA) at a 1:2,000 dilution for 1 hour at room temperature, and with 192 
secondary antibody Dylight 488–conjugated goat anti-mouse IgG (Abcam) at a 1:500 dilution for 193 
1 hour at room temperature. Images were acquired and spot forming units were counted in the 194 
presence of mAb (HCVccSFUtest) or media only (HCVccSFUcontrol) using an AID iSpot Reader 195 
Spectrum operating AID ELISpot Reader version 7.0. Percent neutralization was calculated as 196 
100% x [1-(HCVccSFUtest /HCVccSFUcontrol)]. 197 
 198 
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Antibody variable region gene sequencing. Antibody heavy and light-chain variable region 199 
genes were sequenced from antigen-specific hybridoma lines that had been cloned biologically 200 
from flow cytometry. Total RNA was extracted using the RNeasy Mini kit (Qiagen). A modified 201 
5’RACE (Rapid Amplification of cDNA Ends) approach was utilized similar to (43).  Briefly, 5 202 
µl total RNA was mixed with cDNA synthesis primer mix (10 µM each) and incubated for 2 min 203 
at 70°C and then at 42°C to anneal the synthesis primers (1-3 min). After incubation, a mix 204 
containing 5X first-strand buffer (Clontech), DTT (20mM), 5’ template switch oligo (10 µM), 205 
dNTP solution (10mM each) and 10X SMARTScribe Reverse Transcriptase (Clontech) was 206 
added to the primer-annealed total RNA reaction and incubated for 60 min at 42°C. The first-207 
strand synthesis reaction was purified using the Ampure Size Select Magnetic Bead Kit at a ratio 208 
of 0.6X (Beckman Coulter). Following, a single PCR amplification reaction containing 5 µl first-209 
strand cDNA, 2X Q5 High Fidelity Mastermix (NEB), dNTP (10 mM each), forward universal 210 
primer (10 µM) and reverse primer mix (0.2 µM each in heavy-chain mix, 0.2 µM each in light-211 
chain mix) were subjected to thermal cycling with the following conditions: initial denaturation 212 
for 1 min 30 s followed by 30 cycles of denaturation at 98°C for 10 s, annealing at 60°C for 20 s, 213 
and extension at 72°C for 40 s, followed by a final extension step at 72°C for 4 min. The first 214 
PCR reaction was purified using the Ampure Size Select Magnetic Bead Kit at a ratio of 0.6X 215 
(Beckman Coulter). Amplicon libraries were then prepared according to the Pacific Biosciences 216 
Multiplex SMRT Sequencing protocol and sequenced on a Pacific Biosciences Sequel platform. 217 
Raw sequencing data was demultiplexed and circular consensus sequences (CCS) were 218 
determined using the Pacific Biosciences SMRT Analysis tool suite. The identities of gene 219 
segments and mutations from germlines were determined by alignment using ImMunoGenetics 220 
database (44). 221 
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HCV sequence analysis. Core-E1 nucleotide sequences (366bp) were amplified from 222 
longitudinal plasma samples and divergence calculated using the Tamura-Nei model in Mega 223 
v7.0.21, as previously described (45). E1E2 sequences (GenBank: KJ187972-KJ187978, 224 
KJ187980-KJ187985, KJ187987-KJ187990, KM660628-9) were aligned using Muscle and 225 
trimmed in Bioedit to include only mAb probable binding residues. 226 
 227 
Correlation of mAb neutralization profiles. A neutralization profile was generated for each 228 
mAb by ranking each of the 19 HCVpp by greatest neutralization to least neutralization, as 229 
previously described (37). Pairwise Pearson correlations were calculated between these 230 
neutralization profiles in Prism v7 (Graphpad Software). Neutralization of strain 1a116 HCVpp 231 
was not measured in neutralization assays with C18 mAbs used to generate neutralization 232 
profiles, so this data was omitted from reference mAb neutralization profiles prior to correlation 233 
with C18 mAbs.  234 
 235 
Combination Neutralization Assays. MAbs were tested individually at a total concentration of 236 
50 µg/mL against each HCVpp or HCVcc in the panel. Neutralization by each combination of 237 
mAbs was simultaneously tested at a total concentration of 50 µg/mL (16.7 µg/mL of each 238 
mAb).  239 
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Results 240 
Subject C18 spontaneously cleared one HCV infection and then became persistently 241 
reinfected with a second HCV strain. 242 
At enrollment in the Baltimore Before and After Acute Study of Hepatitis (BBAASH), subject 243 
C18 was HCV seronegative and HCV RNA negative (Fig 1). He became infected with a 244 
genotype 1a HCV strain eight months after enrollment. He experienced an unusual 70 day period 245 
of undetectable viremia beginning approximately 100 days after infection, followed by a return 246 
of detectable viremia with a virus that was likely the same as the initial infecting strain since 247 
both were genetically very similar, based on sequencing of core and E1 genes (nucleotide 248 
divergence < 0.01) (45). He ultimately cleared this first infection without treatment 522 days 249 
after initial infection. Following a period of aviremia that lasted 637 days, subject C18 was 250 
reinfected with a second genetically distinct genotype 1a strain (nucleotide divergence from first 251 
infecting strain=0.11) and remained persistently infected for over 4 years of subsequent follow-252 
up. 253 
 254 
C18 mAbs targeted six distinct antigenic sites based on hierarchical clustering analysis. 255 
We isolated thirteen HCV envelope protein-specific mAbs from subject C18 B cells 1,483 days 256 
after initial infection, which was 642 days after onset of the second, persistent infection (Fig 1). 257 
We performed binding assays using a comprehensive alanine mutant library spanning the 258 
envelope proteins (E1 and E2) of genotype 1a strain H77 HCV to identify E1E2 residues 259 
important for binding of these mAbs. For reference, we also re-analyzed previously published 260 
alanine scanning-E1E2-binding results of thirteen well-characterized mAbs targeting multiple 261 
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distinct antigenic sites on the E1 protein (IGH526), the E2 protein (mAbs targeting AR1, AR2, 262 
and AR3), or the E1E2 heterodimer (mAbs targeting AR4 and AR5) (29, 31). Alanine scanning-263 
E1E2-binding assays for these reference mAbs and C18 mAbs were performed using the same 264 
methods in the same laboratory. Probable binding residues identified in this manner may 265 
contribute directly to the mAb binding epitope, or they may be important for the local structure 266 
of that site. 267 
 268 
We grouped mAbs with shared binding residues using hierarchical clustering analysis based on 269 
binding of these mAbs across the library of alanine mutant E1E2 proteins, as previously 270 
described (26) (Fig 2). The number of mAb clusters in this hierarchical analysis indicated that 271 
C18 mAbs targeted six distinct antigenic sites. Some C18 mAbs clustered with reference mAbs 272 
in this analysis, and others did not. The largest cluster included reference bNAbs AR3A-AR3D, 273 
HEPC3, HEPC74, and HEPC43, which were previously mapped to the AR3 antigenic site (31), 274 
and C18 mAbs HEPC122, HEPC151-1, HEPC153, and HEPC154.  A second cluster included 275 
reference bNAbs AR4A and AR5A as well as two C18 mAbs, HEPC111 and HEPC130. It is 276 
reasonable that reference bNAbs AR4A and AR5A clustered in this analysis, although they did 277 
not compete in E1E2 competition-binding experiments in a prior study (18), since both require 278 
E1 and E2 in complex for binding, and both are thought to bind near the C-terminus of E2. Given 279 
this clustering, we consider AR4 and AR5 a single antigenic region, AR4-5, for the remainder of 280 
this report. A third cluster included reference mAb AR1A and C18 mAb HEPC167. C18 mAbs 281 
HEPC108, HEPC132, HEPC158 and HEPC151-2 formed a cluster that excluded all reference 282 
mAbs, indicating that they bind to a distinct antigenic site (hereafter designated AS108). 283 
Similarly, C18 mAbs HEPC112 and HEPC146 did not cluster with each other or any reference 284 
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mAbs, indicating that each also binds to a distinct antigenic site (hereafter designated AS112 and 285 
AS146, respectively). Taken together, these data indicate that the epitopes of the C18 mAbs 286 
involve six distinct antigenic sites, including previously described AR1, AR3, and AR4-5 287 
antigenic sites as well as non-AR1-5 antigenic sites designated AS108, AS112, and AS146.   288 
 289 
To identify probable binding residues of each C18 mAb and each reference mAb, we ranked 290 
E1E2 residues from greatest to least effect of alanine mutation on binding of each mAb. Since all 291 
C18 mAbs bound native but not denatured E1E2 proteins in an ELISA, indicating that they bind 292 
to conformational epitopes (Fig 3), residues at which alanine mutation reduced binding of all E1 293 
and E1E2-specific mAbs, or all E2 and E1E2-specific mAbs, were excluded as potential binding 294 
residues under the assumption that they reduced mAb binding by globally disrupting protein 295 
folding (29). For each mAb, after exclusion of these global misfolding positions, up to fifteen 296 
residues were selected at which alanine mutation produced the greatest reduction in binding, and 297 
also reduced binding by at least 50% relative to wild type protein binding (Table 1). We then 298 
identified the reference mAb which shared the most probable binding residues with each C18 299 
mAb (Table 2). Similarity of C18 mAbs to reference mAbs ranged from fourteen of fifteen 300 
probable binding residues shared (C18 mAb HEPC111 and reference mAb AR5A) down to two 301 
of fifteen probable binding residues shared (C18 mAb HEPC112 and reference mAb IGH526). 302 
 303 
For each identified antigenic site, probable binding residues of one C18 mAb representative of 304 
each antigenic site and its most closely related reference mAb or mAbs were mapped onto the 305 
HCV E2 ectodomain structure from Flyak et al. (46) (Fig 4). First, we mapped probable binding 306 
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residues of C18 mAbs that clustered with reference mAbs in the hierarchical analysis. As 307 
expected, based on clustering with AR3-site mAbs, C18 mAb HEPC153 probable binding 308 
residues fell in the CD81 binding loop and the front layer of E2, which was comparable to 309 
AR3B, the reference mAb with which it shared the most probable binding residues (Fig 4A). 310 
C18 mAb HEPC111 probable binding residues fell in both E1 and E2 proteins (Fig 4B), which 311 
was expected based upon hierarchical clustering of this mAb with AR4A and AR5A reference 312 
mAbs, which are known to require complexed E1 and E2 for binding (18). Most HEPC167 313 
probable binding residues fell in the central beta sandwich (aa 486-566) and back layer (aa 597-314 
645) of E2, and seven of eleven were shared by reference mAb AR1A (Fig 4C). 315 
 316 
Next, we mapped probable binding residues of mAbs that bound AS108, AS146, and AS112. 317 
HEPC108 probable binding residue fell in the beta sandwich, VR2, VR3, and back layer of E2. 318 
Seven of fifteen HEPC108 probable binding residues were also binding residues for reference 319 
mAb AR1A, and seven of fifteen HEPC108 binding residues were binding residues for reference 320 
mAb AR4A, indicating that AS108 overlaps the AR1 and AR4-5 sites (Fig 4D). HEPC146, 321 
which did not cluster with any other mAbs in Fig 2, demonstrated an unusual binding pattern 322 
with probable binding residues in the CD81 binding loop and the central beta sheet of E2, and 323 
two probable binding residues in E1 (Fig 4E). This mAb shared four of its eight probable 324 
binding residues with HEPC3, its most closely related reference mAb. Finally, HEPC112, which 325 
also did not cluster with any other mAbs in Fig 2, had probable binding residues falling only in 326 
E1 (Fig 4F). Only two of fifteen HEPC112 probable E1 binding residues were also binding 327 
residues for IGH526, an E1-specific reference mAb, suggesting that HEPC112 binds to a novel 328 
antigenic site on E1 (AS112). 329 
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Taken together, these data confirm that C18 mAbs bound six distinct antigenic sites, including 330 
previously described AR1, AR3, and AR4-5 antigenic sites as well as non-AR1-5 antigenic sites 331 
on E1 (AS112) and E2 (AS108 and AS146). These results also demonstrate overlap between 332 
probable binding residues of mAbs targeting the AS108, AR1, and AR4-5 antigenic sites, and 333 
between probable binding residues of mAbs targeting the AR3 and AS146 antigenic sites. 334 
 335 
C18 mAbs formed five groups based on E1E2 competition binding. 336 
To assess relationships among mAbs by a different method, we performed pairwise E1E2 337 
competition-binding experiments with twelve C18 mAbs, grouping mAbs that were mutually 338 
inhibitory, i.e., binding of each mAb inhibited each other mAb in the group and was inhibited by 339 
each other mAb in the group (Fig 5). C18 mAb HEPC132 was not included in this analysis due 340 
to poor ELISA binding. Competition-binding results were largely concordant with hierarchical 341 
clustering analysis in Fig 2. Four C18 mAbs from the AR3 cluster were mutually inhibitory 342 
(HEPC151-1, HEPC122, HEPC154, and HEPC153), as were three C18 mAbs from the AS108 343 
cluster (HEPC108, HEPC158, and HEPC151-2), and two C18 mAbs from the AR4-5 cluster 344 
(HEPC111 and HEPC130).  HEPC146 and HEPC112 each displayed a unique pattern of 345 
inhibition by the panel of blocking antibodies, confirming that each binds to a distinct antigenic 346 
site. Although HEPC167 fell in the AR1 rather than the AS108 hierarchical cluster in Fig 2, it 347 
grouped with AS108 mAbs in the binding competition analysis, which is likely explained by 348 
binding residues shared between AS108 mAbs and HEPC167 (i.e., 11 of 15 HEPC108 probable 349 
binding residues were shared by HEPC167) (Fig 4C-D). Notably, AS108 mAbs did not compete 350 
with HEPC111 or HEPC130 (AR4-5-site mAbs) despite sharing multiple probable binding 351 
residues with these mAbs (i.e., 6 of 15 HEPC108 probable binding residues were shared by 352 
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HEPC111), indicating that these binding residues shared between AS108 and AR4-5 mAbs do 353 
not have a large energetic effect on mAb binding. Alternatively, these shared probable binding 354 
residues could be sites that influence E2 conformation, rather than mAb contact residues. Taken 355 
together, these data demonstrate that with the exception of competition between AS108 mAbs 356 
and HEPC167 (an AR1-site mAb), binding competition results were concordant with 357 
hierarchical clustering analysis. 358 
 359 
MAbs targeting four antigenic sites were broadly neutralizing. 360 
We used a diverse panel of nineteen genotype 1a and 1b HCV pseudoparticles (HCVpp) as well 361 
as genotype 2-6 cell culture viruses (HCVcc) to measure neutralizing breadth of C18 mAbs. The 362 
HCVpp panel comprises 94% of the E1E2 amino acid polymorphisms present at greater than 5% 363 
frequency in a reference panel of 643 genotype 1 HCV isolates from GenBank. Using ≥50% 364 
neutralization as a threshold, neutralizing breadth of the mAbs at a 50 µg/mL concentration 365 
ranged from five of six genotypes, including seventeen of nineteen genotype 1 HCVpp, 366 
neutralized by HEPC153 to zero HCVcc or HCVpp neutralized by HEPC132 (Fig 6). Overall, 367 
eight of thirteen C18 mAbs were broadly neutralizing, defined as greater than 50% neutralization 368 
of strains from at least two genotypes, and more than half of the genotype 1 HCVpp panel. These 369 
bNAbs targeted AR3 (HEPC153, HEPC151-1, HEPC154, HEPC122), AR4-5 (HEPC111, 370 
HEPC130), AS108 (HEPC108), and AS146 (HEPC146). 371 
 372 
In many cases, neutralizing breadth of C18 mAbs was consistent with previously described 373 
neutralizing breadth of closely related reference mAbs. Two of the three most broadly-374 
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neutralizing C18 mAbs (HEPC153 and HEPC151-1) bound at AR3, the target of many 375 
previously-described bNAbs (47). In addition to these AR3-site mAbs, HEPC111 was also 376 
broadly neutralizing (17 of 24 strains (4 of 6 genotypes) neutralized), which was similar to the 377 
previously described neutralizing breadth of closely-related reference mAb AR4A (12 of 19 378 
genotype 1 HCVpp were neutralized by AR4A in (31)). HEPC167, which clustered with the 379 
weakly-neutralizing reference mAb AR1A in the binding analysis, also demonstrated poor 380 
neutralizing breadth against the HCVpp panel (2 of 24 strains (1 of 6 genotypes) neutralized).  381 
 382 
Neutralizing breadth of AS108 mAbs varied widely. HEPC108 was broadly neutralizing (19 of 383 
24 strains (5 of 6 genotypes) neutralized) despite sharing probable binding residues with weakly-384 
neutralizing reference mAb AR1A and weakly-neutralizing C18 mAb HEPC167. Furthermore, 385 
HEPC132, which also bound at AS108 and shared ten of fifteen HEPC108 probable binding 386 
residues, neutralized zero of twenty-four strains, further demonstrating that neutralizing breadth 387 
of mAbs is not determined solely by the antigenic site targeted. HEPC112, which binds a novel 388 
site in E1 (AS112), neutralized seven of twenty-four strains (1 of 6 genotypes), which did not 389 
meet our threshold of broad neutralization. Taken together, these results demonstrate that C18 390 
mAbs targeting known antigenic sites (AR3 and AR4-5) as well as non-AR1-5 antigenic sites 391 
(AS108 and AS146) were broadly neutralizing.  392 
 393 
bNAbs targeting multiple antigenic sites were encoded by IgHV1-69. 394 
We sequenced the heavy and light chain variable gene sequences of each of the mAbs (Table 3). 395 
As we and others have previously observed (19, 31, 32, 48), multiple AR3-site mAbs 396 
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(HEPC122, HEPC151-1, HEPC153) were encoded by the same antibody heavy chain variable 397 
gene segment, VH1-69. Of note, one AR4-5-site mAb (HEPC111) and one AS108-site mAb 398 
(HEPC108) also used VH1-69. Collectively, these data indicate that VH1-69 usage favors broad 399 
neutralization and binding of HCV across multiple distinct antigenic sites. Of note, we also 400 
found that HEPC151-2 and HEPC158, which were biologically cloned from different B cells 401 
using limiting dilution and flow sorting, displayed identical heavy and light chain variable gene 402 
sequences, indicating that this clonotype was relatively frequent among HCV-specific B cells in 403 
this subject. As we have previously observed, all mAbs, including bNAbs, were encoded by 404 
antibody genes with relatively sparse somatic mutations, ranging from 87%-94% identity to their 405 
germline heavy chain VH gene sequences, and 89%-98% identity to their germline light chain 406 
VL gene sequences, indicating that extensive somatic hypermutation was not necessary for 407 
acquisition of broad neutralizing activity. 408 
 409 
Polymorphisms outside of mAb binding sites influence bNAb resistance.  410 
To further investigate the wide variation in neutralization sensitivity of HCVpp to C18 mAbs, we 411 
analyzed conservation of probable binding residues of three mAbs (HEPC111, HEPC153, and 412 
HEPC151-1) across all strains in the HCVpp panel (Fig 7). Conservation or variation at probable 413 
binding residues did not predict neutralization sensitivity or resistance of HCVpp strains. For 414 
example, sensitivity of HCVpp strains to HEPC111 varied more than 30-fold despite 100% 415 
conservation of HEPC111 probable binding residues across all strains. Similarly, two strains 416 
with 100% conservation of HEPC151-1 probable binding residues (1a31 and 1a129) differed by 417 
more than 100-fold in sensitivity to HEPC151-1 neutralization. For HEPC153, a strain that was 418 
highly sensitive to neutralization (1b09) had a substitution relative to the H77 sequence (W437F) 419 
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at a HEPC153 probable binding residue, but a strain that was more than 100-fold more resistant 420 
to HEPC153 (1a31) did not have any substitutions relative to H77 at probable HEPC153 binding 421 
residues. Taken together, these results demonstrate that conservation or lack of conservation of 422 
probable binding residues did not predict neutralization sensitivity or resistance of HCVpp 423 
strains. These results may indicate that not all critical binding residues were identified by our 424 
alanine-scanning analysis. Alternatively, these results might be explained by allosteric effects of 425 
polymorphisms distant from binding epitopes. Prior studies have demonstrated that 426 
polymorphisms in hypervariable region 1 (HVR1) or in the central beta sheet of E2 can exert 427 
allosteric effects that influence neutralization sensitivity of HCV isolates. (37, 49, 50). 428 
 429 
C18 mAbs formed three functional groups based on neutralization profiles. 430 
In addition to providing a measure of neutralizing breadth, the pattern of relative neutralizing 431 
potency across a diverse panel of HCVpp (i.e., the neutralization profile) is unique to each mAb 432 
and can be used to identify functional relationships among mAbs (37, 49). We have previously 433 
demonstrated that polymorphisms distant from binding epitopes can have significant effects on 434 
neutralization sensitivity, so functional relationships among mAbs are not always predicted by 435 
binding to shared or distinct antigenic sites (37, 49). We measured pairwise Pearson correlations 436 
between neutralization profiles of C18 mAbs and previously published neutralization profiles of 437 
reference mAbs (31, 37) to identify mAbs with the most closely related neutralization profiles 438 
(Fig 8). As an internal control, we also repeated neutralization testing of reference mAb HEPC74 439 
in parallel with testing of C18 mAbs. As expected, the neutralization profile of this repeat test of 440 
HEPC74 (HEPC74-test) correlated more closely with the previously published HEPC74 441 
neutralization profile (HEPC74-reference) than with any other reference mAb, demonstrating 442 
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that neutralization profiles of individual mAbs are distinct and reproduceable across independent 443 
experiments (Fig 8A). C18 mAbs fell into three functional groups, which were designated AR3-444 
like, AR1-like, and AR5-like based upon the reference mAb to which they were most 445 
functionally similar (Fig 8B).    446 
 447 
In many cases, neutralization profiles of C18 mAbs correlated best with neutralization profiles of 448 
reference mAbs that bound to the same antigenic site. As shown in Fig 8B, neutralization 449 
profiles of C18 mAbs HEPC153, HEPC122, and HEPC154, which each target the AR3 antigenic 450 
site, showed greatest correlation with reference mAbs AR3B, HEPC43, and AR3A, respectively, 451 
which are also AR3-site mAbs. Neutralization profiles of HEPC111 and HEPC130, which bind 452 
at the AR4-5 antigenic site, each showed greatest correlation with reference mAb AR5A, which 453 
also binds at this site. Similarly, the neutralization profile of HEPC167, which binds at the AR1 454 
antigenic site, correlated best with the neutralization profile of the AR1A reference mAb.     455 
 456 
In other cases, neutralization profiles of C18 mAbs could not be predicted from the antigenic site 457 
targeted. Unexpectedly, the neutralization profile of HEPC151-1, which bound at the AR3 site, 458 
correlated best with reference mAb AR1A. The neutralization profile of HEPC108, which bound 459 
the AS108 site, correlated best with the neutralization profile of AR3A. Neutralization profiles of 460 
HEPC158 and HEPC151-2, two other mAbs binding at AS108, correlated best with the 461 
neutralization profile of reference mAb AR1A, as did the neutralization profile of HEPC112, the 462 
mAb which bound exclusively to residues on the E1 protein. HEPC146, which bound at the 463 
CD81 binding loop of E2, correlated best with reference mAb AR5A. Taken together, these 464 
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results demonstrate that C18 mAbs fell into AR3-like, AR1-like, and AR5-like functional 465 
groups. In many but not all cases, neutralization profiles of C18 mAbs were predicted by the 466 
antigenic site targeted. These results highlight the functional significance of small variations in 467 
binding residues targeted, as well as the important but still poorly-understood role that 468 
polymorphisms distant from mAb binding sites play in bNAb resistance. 469 
 470 
C18 mAbs displayed complementary neutralizing breadth. 471 
Since C18 mAbs fell into three functional groups based on their neutralization profiles, we 472 
hypothesized that these mAbs might display complementation of neutralizing breadth, i.e., that 473 
HCV strains resistant to one mAb might be sensitive to another, leading to improved neutralizing 474 
breadth of the mAbs in combination. It should be noted that this was not an analysis of synergy 475 
or cooperativity between mAbs, but rather a comparison of neutralizing breadth of individual 476 
mAbs vs. combinations when the total mAb concentration was held constant. We assessed for 477 
complementation using two different combinations of three mAbs. For each combination, one 478 
mAb was selected from the AR3-like, AR1-like, and AR5-like functional groups. Individual 479 
mAbs were tested at 50 µg/mL for neutralization of the panel of nineteen HCVpp and five 480 
HCVcc (24 strains total), and each combination was tested at 50 µg/mL total antibody 481 
concentration (i.e., 16.7 µg/mL of each mAb), with neutralization defined as ≥50% inhibition. As 482 
shown in Fig 9A, HEPC146, HEPC153, and HEPC151-1 individually neutralized 15, 19, and 19 483 
strains, respectively, whereas the combination neutralized 22 of 24 strains, confirming that the 484 
individual mAbs were complementary. Results with the second mAb combination were similar 485 
(Fig 9B). HEPC111, HEPC153, and HEPC158 individually neutralized 16, 19, and 2 HCVpp, 486 
respectively. Despite the poor neutralizing activity of HEPC158, these three mAbs in 487 
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combination neutralized 21 of 24 strains, which was more than any individual mAb. Notably, 488 
strain 1a129 HCVpp (genotype 1a) and strain S52 HCVcc (genotype 3a) were resistant to 489 
neutralization by both mAb combinations, and these strains were also resistant to neutralization 490 
by every individual C18 mAb (Figs 9 and 6), making it unlikely that they would be effectively 491 
neutralized by any combination of C18 mAbs. Together, these results confirm that mAbs with 492 
distinct neutralization profiles arising in the same individual can display complementary 493 
neutralizing breadth, but that relatively rare HCV strains demonstrate resistance to multiple 494 
individual bNAbs as well as bNAb combinations.495 
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Discussion 496 
In this study, we isolated thirteen E1E2-specific mAbs from B cells of a single HCV-infected 497 
donor who cleared one genotype 1a infection and then became persistently infected with a 498 
second genotype 1a strain. Based on analysis of probable binding residues, these mAbs bound 499 
six distinct antigenic sites on the E1 protein, the E2 protein, or the E1E2 heterodimer, including 500 
three sites (AS108, AS112, and AS146) that are distinct from previously described AR1-5 and 501 
E1 sites. Notably, mAbs targeting four antigenic sites (AR3, AR4-5, AS108, and AS146) were 502 
broadly neutralizing. These mAbs also displayed distinct patterns of relative neutralizing potency 503 
(i.e., neutralization profiles) across a panel of diverse HCV strains, which led to complementary 504 
neutralizing breadth when they were tested in combination. 505 
 506 
These data support prior studies showing that human mAbs targeting the AR3, AR4, and AR5 507 
antigenic sites are often broadly neutralizing (18, 19), and that bNAbs targeting the AR3 site 508 
develop commonly in individuals who clear HCV infection (31, 32). In contrast with prior 509 
studies, we found that some mAbs targeting non-AR3 and non-AR4-5 antigenic sites also 510 
displayed broad neutralizing activity. Identification here of three non AR1-5 antigenic sites 511 
targeted by neutralizing antibodies (AS108, AS112, and AS146) suggests that mAb isolation 512 
from additional human donors could continue to identify additional bNAb epitopes.  513 
 514 
The E1-specific mAb characterized in this study, HEPC112, is of particular interest since few 515 
human mAbs targeting the E1 protein have previously been described. Prior to this study, two 516 
regions of E1 were identified as mAb targets. IGH526 and the related mAb IGH505, which have 517 
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neutralizing activity across multiple HCV strains, bind predominantly to a linear epitope 518 
spanning amino acids 313-327 near the C-terminus of E1 (30, 51). A weakly-neutralizing mAb 519 
designated H-111 binds to a linear epitope spanning amino acids 192-211 at the N-terminus of 520 
E1 (52). In contrast, HEPC112 appears to bind a distinct, discontinuous site predominantly 521 
spanning amino acids 215-299. Although neutralizing breadth of HEPC112 was relatively 522 
narrow, isolation of this conformation-sensitive mAb with cross-reactivity across multiple 523 
heterologous HCV strains suggests that E1 could be a useful target for vaccine development.  524 
 525 
In addition to the notable neutralizing breadth of individual mAbs, we also found that bNAbs 526 
arising in subject C18 displayed complementary neutralizing breadth. It is possible that this 527 
enhanced neutralizing breadth due to expression of multiple bNAbs in combination explains the 528 
ability of subject C18 to clear one genotype 1a infection. However, the timing of development of 529 
these mAbs remains unclear. In addition, one strain in the heterologous HCVpp panel (1a129) 530 
and one HCVcc strain (S52) were resistant to neutralization by all individual mAbs and both 531 
mAb combinations tested. These holes in the neutralizing repertoire of subject C18, represented 532 
by strain 1a129 and S52 resistance, might explain the persistence of this subject’s second 533 
infection. Further studies using autologous viral envelopes will be necessary to test this 534 
hypothesis. 535 
 536 
This study has important implications for HCV vaccine development. Identification of probable 537 
binding residues that were targeted by multiple bNAbs, as well as probable binding residues 538 
shared by bNAbs and weakly neutralizing mAbs, could guide engineering of vaccine antigens to 539 
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favor induction of antibodies against broadly neutralizing epitopes, while limiting induction of 540 
antibodies targeting non-neutralizing domains. This study also suggests that simultaneous 541 
induction of bNAbs targeting multiple E1E2 domains may be advantageous, so incorporation 542 
into a vaccine of full-length E1E2 might provide an opportunity for induction of multiple, 543 
complementary bNAbs. 544 
 545 
The alanine scanning and binding competition assays used to identify antigenic sites targeted by 546 
C18 mAbs each have limitations. Since most mAbs in this study bind to conformational epitopes, 547 
positions at which mutation to alanine reduced binding could be either energetically important 548 
mAb-E1E2 contact residues, or they could be positions that influence mAb binding allosterically 549 
by altering protein conformation. This is a particularly complex problem for AR4-5-like mAbs, 550 
which require both E1 and E2 in a native complex for binding. We controlled for protein folding 551 
effects by discounting ‘global misfolding positions’ that eliminated binding of all conformational 552 
E1 and E1E2-specific, or all conformational E2 and E1E2-specific mAbs, since these mutations 553 
likely reduced binding by causing misfolding of the E1or E2 proteins. Nevertheless, some 554 
positions identified as probable binding residues may not be true epitope residues. Binding 555 
competition assays have limitations as well. It is well established that some mAbs binding to 556 
adjacent but nonoverlapping epitopes can compete for E1E2 binding (22, 53-55). Conversely, 557 
HEPC74 and AR3C, two mAbs now structurally proven to bind largely overlapping epitopes 558 
(46), displayed minimal binding competition in a prior study (31). Given these limitations, fine 559 
resolution of epitopes targeted by these mAbs may ultimately require generation of mAb-E1E2 560 
crystal structures. 561 
 562 
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An additional limitation of this study was the lack of reference mAbs binding to Domains A-E. It 563 
is possible that AS108, AS146, and AS112 are more closely related to these Domains than to 564 
AR1-5. However, Domains A-E fall in E2 only, so they are not likely to be closely related to 565 
AS112, which falls in E1. Based on previously published critical binding residues (26), Domain 566 
C mAb CBH-7 shares some, but not all critical binding residues with AR1 and AS108 mAbs. 567 
However, unlike weakly neutralizing CBH-7 and AR1A, some AS108 mAbs were broadly 568 
neutralizing. Further studies are needed to better define the differences between the overlapping 569 
AS108/AR1/Domain C regions of the E2 protein. 570 
 571 
In summary, we isolated thirteen HCV envelope protein-specific mAbs from B cells of a single 572 
HCV-infected individual who cleared one genotype 1a infection and then became persistently 573 
infected with a second genotype 1a strain. These mAbs bound six distinct antigenic sites on the 574 
E2 protein, the E1E2 heterodimer, or at a discontinuous site near the N-terminus of E1. Three of 575 
these sites (AS108, AS112, and AS146) were distinct from previously described AR1-5 and E1 576 
sites. Notably, mAbs targeting four antigenic sites were broadly neutralizing (AR3, AR4-5, 577 
AS108, and AS146), and mAbs also displayed complementary neutralizing breadth when they 578 
were tested in combination. Overall, this study demonstrates that HCV bNAb epitopes are not 579 
restricted to previously described antigenic sites, expanding the number of sites that could be 580 
targeted for vaccine development. 581 
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Figure Legends 755 
Figure 1. Subject C18 spontaneously cleared one HCV infection and then became 756 
persistently infected with a second HCV strain. The limit of detection (LOD) of the viral load 757 
assay (50 International Units (IU)/mL) is indicated by a dashed line. Values below the LOD are 758 
set at 25 IU/mL and marked with open circles. The arrow at 1,483 days post infection indicates 759 
the time point at which mAbs were isolated from circulating B cells. 760 
 761 
Figure 2. C18 mAbs targeted six distinct antigenic sites. Hierarchical clustering of thirteen 762 
C18 mAbs (in bold type) and thirteen reference mAbs based on Ward’s minimal variance 763 
analysis of mAb binding to a library of strain H77 E1E2 proteins with single alanine mutations 764 
spanning the full E1E2 sequence, depicted as an unrooted tree. Bootstrap values greater than 80 765 
are shown. MAbs that clustered together with bootstrap values >90 were highlighted in the same 766 
color and given a label indicating a previously described (AR1, AR2, AR3, AR4-5) or novel 767 
(AS108, AS112, AS146) antigenic site. 768 
 769 
Figure 3. Conformational E1E2 binding. Binding of C18 mAbs to native and denatured E1E2 770 
proteins. HEPC85 and HEPC3 bind to linear and conformational epitopes, respectively, and are 771 
shown as controls (31). 772 
 773 
Figure 4. Mapping of probable binding residues of each mAb onto the E2 ectodomain 774 
crystal structure. One C18 mAb representative of each antigenic cluster in Fig 2 is shown, with 775 
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the reference mAb or mAbs with which is shares the most probable binding residues: (A) 776 
HEPC153 (B) HEPC111 (C) HEPC167 (D) HEPC108 (E) HEPC146 (F) HEPC112. For each 777 
mAb, up to fifteen probable E2-binding residues are shown, marked with colored spheres on the 778 
HCV E2 structure (Flyak et al., PDB 6MEI, (46)). Probable E1-binding residues are shown in 779 
tabular form. These fifteen E1E2 binding residues were also subdivided into tertiles of greatest 780 
effect (magenta), middle effect (orange), and least effect (yellow) of mutation to alanine on mAb 781 
binding. E2 structural components were highlighted in PyMOL, including the AS412 site 782 
(purple), front layer (cyan), VR2 (brown), CD81 binding loop (blue), beta sandwich (red), VR3 783 
and post-VR3 (gray), and back layer (green). Dashed line indicates the stalk region of E2 not 784 
present in the ectodomain structure. MAb names are color-coded according to hierarchical 785 
clustering in Fig 2. 786 
 787 
Figure 5. C18 mAbs formed five groups based on E1E2 competition binding. Percent 788 
inhibition of binding of 2 µg/mL or 0.4 µg/mL of biotinylated mAbs to E1E2 proteins in an 789 
ELISA in the presence of blocking mAbs at a concentration of 20 µg/mL. Squares at the 790 
intersection between blocking and biotinylated mAbs are color-coded by the degree of inhibition. 791 
Groups of mAbs that were mutually inhibitory (i.e., binding of each mAb inhibited each other 792 
mAb in the group and was inhibited by each other mAb in the group) are marked with thick 793 
black boxes. Values are averages of three independent experiments, each performed in duplicate. 794 
MAb names are color-coded according to hierarchical clustering in Fig 2. Data not available is 795 
marked ‘na’.  796 
 797 
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Figure 6. MAbs targeting four antigenic sites were broadly neutralizing. Neutralizing 798 
breadth of the C18 mAbs was measured using a diverse panel of genotype 1a and 1b HCV 799 
pseudoparticles (HCVpp) and genotype 2-6 HCVcc. Percent neutralization of each strain by each 800 
mAb at a 50 µg/mL concentration is shown, with HCVpp or HCVcc on the y-axis and mAbs 801 
arranged from greatest to least neutralizing breadth on the x-axis. HCVpp values are averages of 802 
two independent experiments, each performed in duplicate. HCVcc values are from a single 803 
experiment performed in duplicate. MAb names are color-coded according to hierarchical 804 
clustering in Fig 2.  805 
 806 
Figure 7. Polymorphisms outside of mAb binding sites influence bNAb resistance. Amino 807 
acids present at probable binding residues of HEPC111 (A), HEPC153 (B), and HEPC151-1 (C) 808 
across all strains in the HCVpp panel. Homology to the strain H77 sequence is indicated with a 809 
dot. Percent neutralization of each HCVpp strain by 50 µg/mL of each mAb are shown. Values 810 
are averages of two independent experiments, each performed in duplicate. For each mAb, full 811 
neutralization curves were also measured in duplicate with five-fold serial dilutions of mAb 812 
starting at 100 µg/mL for one sensitive and two more resistant HCVpp strains. Error bars 813 
indicate standard deviations. MAb names are color-coded according to hierarchical clustering in 814 
Fig 2.   815 
 816 
Figure 8. C18 mAbs formed three functional groups based on neutralization profiles. 817 
Neutralization of eighteen HCVpp by 50 µg/mL of each mAb was measured in duplicate, 818 
generating a neutralization profile for each mAb (i.e., a ranking of HCVpp strains by relative 819 
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neutralization sensitivity). Pearson’s correlations were measured between these C18 mAb 820 
neutralization profiles and neutralization profiles of reference mAbs. (A) Neutralization testing 821 
of reference mAb HEPC74 was performed in parallel with testing of C18 mAbs. Correlation was 822 
measured between the neutralization profile of this repeat test of HEPC74 (HEPC74-test) and the 823 
previously published HEPC74 neutralization profile (HEPC74-reference, left) or an unrelated 824 
mAb (AR5A-reference, right). Each point indicates a single HCVpp, with rank of neutralization 825 
sensitivity to one mAb on the x axis and another mAb on the y axis. (B) Pearson r values of 826 
pairwise correlations between neutralization profiles of each C18 mAb (y axis) and each 827 
reference mAb (x axis). Only r values that are statistically significant (p<0.05) are shown, and 828 
darker green color indicates a stronger positive correlation. The highest r value for each C18 829 
mAb is boxed and in bold type. C18 mAbs clustered into three functional groups: AR3-like, 830 
AR1-like, and AR5-like. 831 
 832 
Figure 9. C18 mAbs displayed complementary neutralizing breadth. C18 mAbs were tested 833 
for neutralization of the HCVpp and HCVcc panels individually at 50 µg/mL or in two different 834 
3-mAb combinations at 50 µg/mL total antibody concentration (i.e., 16.7 µg/mL of each mAb): 835 
(A) HEPC146, HEPC153, HEPC151-1; (B) HEPC111, HEPC153, HEPC158. Lines connect 836 
neutralization of each HCV strain by each individual mAb and the 3-mAb combination. Blue 837 
lines indicate strains not neutralized >50% by the mAb combination. MAb names are color-838 
coded according to hierarchical clustering in Fig 2. Percent neutralization values are the average 839 
of duplicate measurements. 840 
 841 
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Table 1. Probable E1E2-binding residues for each C18 mAb and reference mAb. 
 
 
Antigenic 
Site 
C18 
mAb Probable Binding Residues 
Reference 
mAb 
Probable Binding Residues 
AR1 
HEPC-
167 
R543 P544 P545 L546 G547 N548 W549 Y594 
C597 G598 G635 
AR1A Y485 P498 G517 T519 N532 T534 P544 P545 
G547 N548 W549 C597 G635 W646 D653 
AR3 
HEPC-
122 
I422 T425 N428 C429 L441 H445 C503 T518 
D520 G523 W529 G530 D535 W616 C620 
AR3A T425 N428 C429 G436 W437 L438 G440 L441 
F442 Y485 C503 W529 G530 D535 W616 
HEPC-
151-1 
T425 L427 N428 C429 W437 A499 C503 V515 
T518 D520 G523 W529 G530 D535 
AR3B T425 L427 N428 C429 W437 G440 L441 F442 
C503 D520 G523 W529 G530 D535 W616 
HEPC-
153 
T425 L427 N428 C429 W437 L441 F442 C503 
T519 D520 G523 Y527 W529 D535 W616 
AR3C T425 N428 C429 W437 L438 G440 L441 F442 
Y443 A499 C503 W529 G530 D535 W616 
HEPC-
154 
L356 N428 C429 W437 F442 A499 K500 C503 
V515 G523 G530 D535 P605 G635 T647 
AR3D T425 L427 N428 C429 G436 W437 G440 L441 
F442 C503 T518 D520 G530 D535 W616 
 HEPC3 T425 L427 N428 G436 W437 L438 L441 F442 
C503 G517 T518 D520 W529 G530 D535 
HEPC74 S424 T425 L427 N428 C429 G436 W437 A499 
C503 T518 T519 D520 G523 G530 D535 
HEPC43 S424 T425 L427 N428 C429 W437 L441 A499 
C503 T518 T519 D520 G523 G530 D535 
AR4-5 
HEPC-
111 
Y201 N205 C486 R543 C569 G573 C585 F586 
Y594 C597 G635 C652 R657 D658 C677 
AR4A Y201 N205 C486 W487 R543 P545 C569 C585 
Y594 C597 G635 C652 R657 C677 D698 
HEPC-
130 
Y201 N205 C486 W487 R543 P544 P545 C569 
G573 C585 Y594 C597 G635 C652 C677 
AR5A Y201 N205 C486 W487 R543 C569 G573 C585 
Y594 C597 G635 C652 R657 D658 C677 
AS108 
HEPC-
108 
I472 Y474 R543 P544 P545 L546 G547 N548 
W549 C569 C585 Y594 C597 G598 G635 
 
HEPC-
151-2 
I472 Y474 R543 P544 P545 G547 N548 W549 
C569 G573 T593 Y594 C597 G598 G635 
HEPC-
132 
 
I472 C486 R543 P544 P545 W549 C569 C581 
C585 H589 E591 Y594 R596 C597 G635 
HEPC-
158 
I472 Y474 C486 R543 P544 P545 L546 G547 
N548 W549 C569 Y594 C597 G598 G635 
AS146 
HEPC-
146 
D321 A330 G517 D520 W529 T534 D535 
W549 
 
AS112 
HEPC-
112 
E215 E232 G233 V246 R249 K252 R259 R260 
D263 R297 W299 G354 Y361 F378 D382 
 
E1 C-
terminus 
 IGH526 H316 M324 M323 Q336 W320 D321 C652 D653 
T329 Y361 E215 G315 K588 N325 G573 
HVR1  HEPC98 L402 P405 K408 
AR2  AR2A S557 L615 F627 T647 
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Table 2. Reference mAbs sharing the greatest number of probable binding residues with 
each C18 mAb. 
C18 mAb Reference mAb Shared Residues Involved 
in Epitope Formation 
HEPC153 AR3B 13 
HEPC151-1 HEPC43, HEPC74 12 
HEPC122 AR3B 11 
HEPC154 AR3B 8 
HEPC111 AR5A 14 
HEPC130 AR4A, AR5A 13 
HEPC167 AR1A 7 
HEPC108 AR1A, AR4A 7 
HEPC158 AR4A 7 
HEPC151-2 AR4A, AR5A 6 
HEPC132 AR4A 8 
HEPC146 HEPC3 4 
HEPC112 IGH526 2 
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Table 3. Germline origin genes and variable region analysis of subject C18 mAbs. 
 
Antigenic 
Site mAb 
Heavy chain variable gene sequence Light chain variable sequence 
 
V-gene and 
allele 
V-region 
nucleotide 
homology 
to V-gene, 
% 
 
D-gene and 
allele 
 
J-gene and 
allele 
 
CDR3 
amino acids (aa) 
 
CDR3 
length 
(aa) 
 
V-gene and 
allele 
 
V-region 
nucleotide 
homology 
to V gene, 
% 
 
J-gene and 
allele 
 
CDR3 
amino acids 
(aa) 
 
CDR3 
length 
(aa) 
 
AR1 HEPC-167 IGHV1-18*04 91.7 IGHD3-16*01 IGHJ4*03 ARDSVTGGMDV 11 IGLV3-25*03 92.8 IGLJ3*02 QFADISGTYRRV 12 
AR3 
HEPC-122 IGHV1-69*17 93.8 IGHD3-3*01 IGHJ4*02 ATFDYDFYSGAPSRSYFVH 19 IGKV3-20*01 97.2 IGKJ4*01 QQYGSSPT 8 
HEPC-151-1 IGHV1-69*01 87.9 IGHD3-10*01 IGHJ6*02 ARDGGGHSGLGRFYDLNGMDV 21 IGKV3-15*01 95.3 IGKJ2*01 QQYDNWPPRYT 11 
HEPC-153 IGHV1-69*01 92.7 IGHD1-20*01 IGHJ5*02 VREMRYNWNPGRSSWFDP 18 IGKV3-11*01 93.6 IGKJ3*01 QQRSIRPPS 9 
HEPC-154 IGHV3-53*01 88.8 IGHD3-16*01 IGHJ3*02 ARCFAGLMAMDI 12 IGKV2-28*01 97.3 IGKJ3*01 MQGLQIPPT 9 
AR4-5 
HEPC-111 IGHV1-69*01 91.7 IGHD3-3*01 IGHJ3*01 ARSEDVLSGYYSVSIDAFNV 20 IGLV1-51*01 94.0 IGLJ2*01 ATWDRSLSIAV 11 
HEPC-130 IGHV3-30*03 87.2 IGHD2-2*01 IGHJ6*02 ARNSVPATMTSYYFYALDL 19 IGKV1-39*01 88.9 IGKJ1*01 LQTYDTVWT 9 
AS108 
HEPC-108 IGHV1-69*06 94.1 IGHD6-19*01 IGHJ4*02 ARASIVNISGFVRFRFDS 18 IGKV1-33*01 95.7 IGKJ2*01 QHYDDVPPVYT 11 
HEPC-151-2 IGHV1-18*04 89.6 IGHD3-22*01 IGHJ3*02 ARHDSSGYEALDI 13 IGLV3-19*01 97.9 IGLJ1*01 NSRDTSPYHHFV 12 
HEPC-132 
 IGHV4-31*03 91.8 IGHD3-3*01 IGHJ6*02 ARDGADGFWSGHNFGMDA 
18 IGKV3-11*01 93.6 IGKJ4*01 QQRSAWPRT 9 
HEPC-158 IGHV1-18*04 89.6 IGHD3-22*01 IGHJ3*02 ARHDSSGYEALDI 13 IGLV3-19*01 97.9 IGLJ1*01 NSRDTSPYHHFV 12 
AS146 HEPC-146 IGHV4-61*01 92.1 IGHD5-24*01 IGHJ1*01 ARTSQMTTLLL 11 IGLV2-8*01 94.4 IGLJ3*02 SSYVGNDNLL 10 
AS112 HEPC-112 IGHV3-48*03 92.4 IGHD3-3*01 IGHJ4*02 VRDGREFWGGSRIPFDH 17 IGKV3-20*01 95.0 IGKJ2*01 QQYATTPDT 9 
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